| CAS NO: | 88889-14-9 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 88889-14-9 |
| 别名 | 福辛普利钠; SQ28555 |
| Canonical SMILES | O=C(N1[C@H](C([O-])=O)C[C@@H](C2CCCCC2)C1)CP(CCCCC3=CC=CC=C3)(O[C@H](OC(CC)=O)C(C)C)=O.[Na+] |
| 分子式 | C30H45NO7P.Na |
| 分子量 | 585.7 |
| 溶解度 | Methanol: 1 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Fosinopril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor fosinoprilat.1Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol/kg, respectively. Fosinopril (2.5 mg/kg) reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure.2Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure. 1.DeForrest, J.M., Waldron, T.L., Harvey, C., et al.Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: In vitro and preclinical in vivo pharmacologyJ. Cardiovasc. Pharmacol.14(5)730-736(1989) 2.McElmurray, J.H., III, Mukherjee, R., New, R.B., et al.Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometryJ. Pharmacol. Exp. Ther.291(2)799-811(1999) |
m.cnreagent.com